Case Study: Memorial Sloan Kettering Cancer Center expands liquid biopsy access with SOPHiA GENETICS

Memorial Sloan Kettering Cancer Center expands liquid biopsy access with SOPHiA GENETICS, backed by 99.4% concordance

Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer treatment and research institution, sought to expand global access to its highly validated MSK-ACCESS® liquid biopsy test. Their challenge was to scale this robust genomic profiling technology and make it available to more patients and clinicians outside of their own facility. To achieve this, they collaborated with vendor SOPHiA GENETICS.

The solution implemented by SOPHiA GENETICS was to power MSK-ACCESS® with its decentralized, cloud-based SOPHiA DDM™ Platform. This collaboration created a streamlined sample-to-report workflow that maintains the test's high analytical performance. The measurable impact is a demonstrated 99.4% end-to-end concordance with the original MSK-ACCESS® test, providing trusted performance for decentralized use. SOPHiA GENETICS' platform allows labs worldwide to perform the analysis locally while retaining control of their data and samples.

Memorial Sloan Kettering Cancer Center